DeutschNewstral
Article
bizjournals.com on 2017-05-02 16:50
Cambridge's bluebird bio licenses delivery tech to Novartis, GSK
Related news
- Cambridge's bluebird bio expanding Kendall Square HQbizjournals.com
- Exec at Cambridge's bluebird bio heads to startup Be Biobizjournals.com
- Executive pay at Cambridge's bluebird bio took a nosedive in 2020bizjournals.com
- LHemoglobinopathy Testing Services Market Size, Historical Growth, Analysis, Opportunities and Forecast to2028| Novartis, AstraZeneca, Bluebird Bioliverpoolstudentmedia.com
GSK completes transaction with Novartisabc3340.com- GSK stares at $1 billion in royalties following deal with Novartisbizjournals.com
- LGlobal Sickle Cell Market Estimation 2021-2026 Analysis by Key Players like Novartis, Bristol-Myers Squibb, Takeda, Bluebird Bio, Global Blood Therapeutics,, etc. | Affluenceliverpoolstudentmedia.com
- GSK, Novartis complete complex, multibillion-dollar dealbizjournals.com
Bluebird Bio Sickle-Cell Therapy Helped Teenwsj.com
Novartis sells joint venture stake to GSK for $13 billionsanluisobispo.com
GSK sees drop in earnings after asset swap with Novartisreviewtimes.com- FNovartis sells stake in joint venture to GSK for $13bnft.com
- WGSK, Novartis wrap up $21B asset swap, form joint venturewraltechwire.com
- FNovartis and GSK CEOs set out diverging strategiesft.com
- Novartis sells stake in consumer business to GSK for $13bnbizjournals.com